金斯瑞(01548.HK)收到禮新就抗PD-1單域抗體許可協議項下2.14億美元付款
金斯瑞生物科技(01548.HK)公布,有關其非全資附屬南京蓬勃同意授予禮新一項獨家全球可轉讓許可,許可專利披露抗PD-1單域抗體和相關專有技術,蓬勃已收到經重述及經修訂許可協議項下約2.14億美元(扣除代扣代繳所得稅後)的付款。
該等付款由首付款、達成首個里程碑獲得的里程碑付款及與經重述及經修訂許可協議項下經許可的抗PD-1單域抗體有關的分許可收入。
抗PD-1單域抗體被用於禮新開發的在研PD1/VEGF雙特異性抗體LM-299,該雙特異性抗體LM-299已獲得新藥臨床研究批准。
公司認為,該等款項的到賬將進一步充盈蓬勃的現金儲備並增強其核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.